Pliva Pharma Limited - search results

Ireland - English - HPRA (Health Products Regulatory Authority)

omsil capsules modified release 400 microgram

pliva pharma limited - tamsulosin hydrochloride - capsules modified release - 400 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

clarithromycin 500mg milligram coated tablets

pliva pharma limited - clarithromycin - coated tablets - 500mg milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

clarithromycin 250mg milligram coated tablets

pliva pharma limited - clarithromycin - coated tablets - 250mg milligram

European Union - English - EMA (European Medicines Agency)

budesonide/formoterol teva pharma b.v.

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

European Union - English - EMA (European Medicines Agency)

pioglitazone teva pharma

teva pharma b.v. - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,